Emergence of nosocomial associated opportunistic pathogens in the gut microbiome after antibiotic treatment

Abstract

Introduction According to the Centers for Disease Control’s 2015 Hospital Acquired Infection Hospital Prevalence Survey, 1 in 31 hospital patients was infected with at least one nosocomial pathogen while being treated for unrelated issues. Many studies associate antibiotic administration with nosocomial infection occurrence. However, to our knowledge, there is little to no direct evidence of antibiotic administration selecting for nosocomial opportunistic pathogens. Aim This study aims to confirm gut microbiota shifts in an animal model of antibiotic treatment to determine whether antibiotic use favors pathogenic bacteria. Methodology We utilized next-generation sequencing and in-house metagenomic assembly and taxonomic assignment pipelines on the fecal microbiota of a urinary tract infection mouse model with and without antibiotic treatment. Results Antibiotic therapy decreased the number of detectable species of bacteria by at least 20-fold. Furthermore, the gut microbiota of antibiotic treated mice had a significant increase of opportunistic pathogens that have been implicated in nosocomial infections, like Acinetobacter calcoaceticus/baumannii complex, Chlamydia abortus, Bacteroides fragilis, and Bacteroides thetaiotaomicron. Moreover, antibiotic treatment selected for antibiotic resistant gene enriched subpopulations for many of these opportunistic pathogens. Conclusions Oral antibiotic therapy may select for common opportunistic pathogens responsible for nosocomial infections. In this study opportunistic pathogens present after antibiotic therapy harbored more antibiotic resistant genes than populations of opportunistic pathogens before treatment. Our results demonstrate the effects of antibiotic therapy on induced dysbiosis and expansion of opportunistic pathogen populations and antibiotic resistant subpopulations of those pathogens. Follow-up studies with larger samples sizes and potentially controlled clinical investigations should be performed to confirm our findings.

Host factors facilitating SARS‐CoV‐2 virus infection and replication in the lungs

“…By occupying the niche, the commensals microbes avoid the growth of potentially harmful pathogens [ 171 ]. Furthermore, a dysbiosis in the microbiome will triggers a change from commensal relationship to pathogenic relationship [ 269 , 270 ]. In many cases, the decrease of diversity will increase the competition between the survivors and highly competitive opportunistic pathogens such as ESKAPE pathogens or Staphylococcus will become the dominant member of the microbiome.…”

New science, drug regulation, and emergent public health issues: The work of FDA’s division of applied regulatory science

“…In particular, DARS developed a cell-based method to measure the rate at which antibiotic resistance appears. This hollow fiber bioreactor system ( 116 ) administers drugs to cells using human pharmacokinetic profiles to identify drug combinations that slow the development of resistance. Next-generation sequencing is being used to investigate the genetic and epigenetic biomarkers of antibiotic resistance and to investigate the effects of combinations of oral antibiotics on bacterial genomes and the gut microbiome ( 117 ) high-through put screening assay to identify optimal drug combinations for different organisms.…”

Bioengineered Probiotics: Synthetic Biology Can Provide Live Cell Therapeutics for the Treatment of Foodborne Diseases

“…Competition with the endogenous community, coupled with the host’s immune system, can often control infections. Indeed, some opportunistic pathogens are commonly resident in the gut of most mammals but do not trigger disease unless the endogenous microbial community is disrupted by stress or more often in response to antibiotic drugs that decimate the resident microbes creating an opportunity for pathogenic strains to rapidly expand ( Raplee et al, 2021 ; Abd El-Hack et al, 2022 ).…”